Document is current
Any future updates will be listed below
-
Authors
Phi, Lan T. H.
Cheng, Yating
Funakoshi, Yohei
Bertucci, Francois
Finetti, Pascal
Van Laere, Steven J.
Zou, Fang
Long, James P.
Ogata, Suguru
Krishnamurthy, Savitri
Reuben, James M.
Foulks, Jason M.
Warner, Steven L.
Rosenbluth, Jennifer M.
Sood, Anil K.
Tripathy, Debu
Ueno, Naoto T.
Wang, Xiaoping
-
Funding
Funding for this research was provided by:
National Institutes of Health (1R01CA205043-01A1)
Breast Cancer Research Foundation (BCRF-23-164)
U.S. Department of Defense (W81XWH-21-1-0559)
MD Anderson Institutional Research Grant
Alligator’s Hunt for Hope Adventure Fund
- License Information
-
More Information
Article History
Received: 24 September 2024
Accepted: 3 April 2025
First Online: 6 May 2025
Declarations
:
: Animal experiments were approved by the MD Anderson Institutional Animal Care and Use Committee (protocol 00001072).
: Not applicable.
: NTU holds consulting roles with AstraZeneca, Bayer, Pfizer, Gilead Sciences, Chugai Pharmaceutical, Daiichi Sankyo, Eisai Co., KeChow Pharma, Lavender Health, OBI Pharma, OncoCyte, Ourotech, DBA Pear Bio, Kirilys Therapeutics, Phoenix Molecular Designs, Preferred Medicine, Puma Biotechnology, Sumitomo Dainippon Pharma, Sysmex Co., Takeda Pharmaceuticals, CARNA Biosciences, ChemDiv, DualityBio, Oncolys BioPharma, Rakuten Medical, Merck, AnHeart Therapeutics, Carisma Therapeutics, and Eli Lilly. He also holds speaker or preceptorship roles with Bristol-Myers Squibb, Chugai Pharmaceutical, Genomic Health, Kyowa Hakko Kirin Co., Sumitomo Dainippon Pharma, and Medscape. He also has research agreements in place with AnHeart Therapeutics, Eisai Co., Gilead Sciences, Phoenix Molecular Designs, Daiichi Sankyo, Puma Biotechnology, Merck, Oncolys BioPharma, OBI Pharma, ChemDiv, Tolero Pharmaceuticals, and VITRAC Therapeutics. AKS is a shareholder of BioPath and a consultant for Merck, AstraZeneca, Onxeo, ImmunoGen, Ivlon, GSK, and Kiyatec. DT receives funding for research (paid to MD Anderson Cancer Center) from Novartis and AMBRX. He receives consulting fees from AstraZeneca, OncoPep, GlaxoSmithKline, Gilead, Personalis, Sermonix, Pfizer, AMBRX, Novartis, Puma Biotechnology, Roche, Menarini, BeiGene, and Jazz Pharmaceuticals. AKS is a shareholder of BioPath and a consultant for Merck, AstraZeneca, Onxeo, ImmunoGen, Ivlon, GSK, and Kiyatec. DT receives funding for research (paid to MD Anderson Cancer Center) from Novartis and AMBRX. He receives consulting fees from AstraZeneca, OncoPep, GlaxoSmithKline, Gilead, Personalis, Sermonix, Pfizer, AMBRX, Novartis, Puma Biotechnology, Roche, Menarini, BeiGene, and Jazz Pharmaceuticals.
